Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Influenza

  Free Subscription


Articles published in Antimicrob Agents Chemother

Retrieve available abstracts of 27 articles:
HTML format



Single Articles


    July 2020
  1. GORDY JT, Mazumdar K, Dutta NK
    Accelerating Drug Development through Repurposed FDA-Approved Drugs for COVID-19: Speed Is Important, Not Haste.
    Antimicrob Agents Chemother. 2020;64.
    PubMed    


  2. DANION F, Ruch Y, Fourtage M, Kaeuffer C, et al
    The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19.
    Antimicrob Agents Chemother. 2020;64.
    PubMed    


  3. SALGADO-BENVINDO C, Thaler M, Tas A, Ogando NS, et al
    Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available


  4. MARATHE BM, Asthagiri Arunkumar G, Vogel P, Pascua PNQ, et al
    Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus.
    Antimicrob Agents Chemother. 2020 Jul 6. pii: AAC.00284.
    PubMed     Abstract available


    June 2020
  5. SOFTIC L, Brillet R, Berry F, Ahnou N, et al
    Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available


  6. JEON S, Ko M, Lee J, Choi I, et al
    Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available


    May 2020
  7. HOFFMANN M, Schroeder S, Kleine-Weber H, Muller MA, et al
    Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19.
    Antimicrob Agents Chemother. 2020;64.
    PubMed    


  8. LI H, Zhou Y, Zhang M, Wang H, et al
    Updated Approaches against SARS-CoV-2.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available


  9. LIM JJ, Nilsson AC, Silverman M, Assy N, et al
    A phase 2 randomized, double-blind, placebo-controlled trial of MHAA4549A, a monoclonal antibody, plus oseltamivir in patients hospitalized with severe influenza A infection.
    Antimicrob Agents Chemother. 2020 May 11. pii: AAC.00352.
    PubMed     Abstract available


  10. ADAMS SE, Lugovtsev VY, Kan A, Bovin NV, et al
    Laninamivir-Interferon-lambda1 Combination Treatment Promotes Resistance by Influenza A Virus More Rapidly Than Laninamivir Alone.
    Antimicrob Agents Chemother. 2020 May 11. pii: AAC.00301.
    PubMed     Abstract available


    April 2020
  11. KOSHIMICHI H, Retout S, Cosson V, Duval V, et al
    Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Patients Infected with Influenza at High Risk of Influenza Complications.
    Antimicrob Agents Chemother. 2020 Apr 20. pii: AAC.00119.
    PubMed     Abstract available


  12. ZHAO L, Yan Y, Dai Q, Li X, et al
    Development of Novel Anti-influenza Thiazolides with Relatively Broad-spectrum Antiviral Potentials.
    Antimicrob Agents Chemother. 2020 Apr 20. pii: AAC.00222.
    PubMed     Abstract available


  13. NGUYEN CT, Suzuki S, Itoh Y, Ishigaki H, et al
    Efficacy of neuraminidase inhibitors against H5N6 highly pathogenic avian influenza virus in a non-human primate model.
    Antimicrob Agents Chemother. 2020 Apr 13. pii: AAC.02561.
    PubMed     Abstract available


    March 2020
  14. MARTINEZ MA
    Compounds with therapeutic potential against novel respiratory 2019 coronavirus.
    Antimicrob Agents Chemother. 2020 Mar 9. pii: AAC.00399.
    PubMed     Abstract available


    September 2018
  15. FARRUKEE R, Zarebski AE, McCaw JM, Bloom JD, et al
    CHARACTERIZATION OF INFLUENZA B VIRUS VARIANTS WITH REDUCED NEURAMINIDASE INHIBITOR SUSCEPTIBILITY.
    Antimicrob Agents Chemother. 2018 Sep 10. pii: AAC.01081.
    PubMed     Abstract available


    August 2018
  16. ALI SO, Takas T, Nyborg A, Shoemaker K, et al
    Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.
    Antimicrob Agents Chemother. 2018 Aug 27. pii: AAC.00694.
    PubMed     Abstract available


    June 2018
  17. YOON JJ, Toots M, Lee S, Lee ME, et al
    Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses.
    Antimicrob Agents Chemother. 2018 Jun 11. pii: AAC.00766.
    PubMed     Abstract available


    March 2018
  18. VIGIL A, Estelles A, Kauvar LM, Johnson SK, et al
    Native human monoclonal antibodies with potent cross-lineage neutralization of influenza B viruses.
    Antimicrob Agents Chemother. 2018 Mar 5. pii: AAC.02269.
    PubMed     Abstract available


    January 2018
  19. MCBRIDE JM, Lim JJ, Burgess T, Deng R, et al
    Reply to Hunsberger and Memoli, "Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat".
    Antimicrob Agents Chemother. 2017;62.
    PubMed    


  20. HUNSBERGER S, Memoli MJ
    Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat.
    Antimicrob Agents Chemother. 2017;62.
    PubMed    


    November 2017
  21. TSUJI BT, Fisher J, Boadi-Yeboah R, Holden PN, et al
    Azithromycin Pharmacodynamics against 'Persistent' Haemophilus influenza in Chronic Obstructive Pulmonary Disease.
    Antimicrob Agents Chemother. 2017 Nov 27. pii: AAC.01995.
    PubMed     Abstract available


    August 2017
  22. MCBRIDE JM, Lim JJ, Burgess T, Deng R, et al
    Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Challenge Model: A Phase 2 Randomized Trial.
    Antimicrob Agents Chemother. 2017 Aug 14. pii: AAC.01154.
    PubMed     Abstract available


    May 2017
  23. LIM JJ, Derby MA, Zhang Y, Deng R, et al
    A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Monoclonal Antibody, MHAB5553A, in Healthy Volunteers.
    Antimicrob Agents Chemother. 2017 May 30. pii: AAC.00279.
    PubMed     Abstract available


    April 2017
  24. STAROSILA D, Rybalko S, Varbanetz L, Ivanskaya N, et al
    Anti-influenza activity of Bacillus subtilis probiotic strain.
    Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.00539.
    PubMed     Abstract available


  25. GAILLARD V, Galloux M, Garcin D, Eleouet JF, et al
    A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Abstract available


    March 2017
  26. GRIFFIN MP, Khan AA, Esser MT, Jensen K, et al
    Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Abstract available


    February 2017
  27. JONES JC, Marathe BM, Vogel P, Gasser R, et al
    The PA endonuclease inhibitor RO-7 protects mice from lethal challenge with influenza A or B viruses.
    Antimicrob Agents Chemother. 2017 Feb 13. pii: AAC.02460.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: